Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

• Published in: The American heart journal Vol. 168; no. 1; pp. 23 - 29.e2
• Main Authors: Holman, Rury R., FRCP, Bethel, Mary A., MD, Chan, Juliana C.N., MD, Chiasson, Jean-Louis, MD, Doran, Zoë, RN, Ge, Junbo, MD, Gerstein, Hertzel, MD, MSc, Huo, Yong, MD, McMurray, John J., MD, Ryden, Lars, MD, PhD, Liyanage, Winitha, MSc, Schröder, Stefan, PhD, Tendera, Michal, MD, Theodorakis, Michael J., MD PhD, Tuomilehto, Jaakko, MD, MA, PhD, Yang, Wenying, MD, Hu, Dayi, MD, Pan, Changyu, MD
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.07.2014; Elsevier Limited
• Subjects: Acarbose - therapeutic use; Blood Glucose - drug effects; Blood Glucose - metabolism; Cardiovascular; Cardiovascular disease; Coronary Disease - blood; Coronary Disease - complications; Coronary Disease - prevention & control; Coronary vessels; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - prevention & control; Disease Progression; Double-Blind Method; Drug therapy; Follow-Up Studies; Glucose Intolerance - blood; Glucose Intolerance - complications; Glucose Intolerance - drug therapy; Heart attacks; Humans; Hyperglycemia; Hypoglycemic Agents - therapeutic use; Medicin och hälsovetenskap; Older people; Prospective Studies; Secondary Prevention - methods; Treatment Outcome; Hong Kong; China
• ISSN: 0002-8703; 1097-6744; 1097-6744
• DOI: 10.1016/j.ahj.2014.03.021

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.